Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Class I Drug Recall Notification: Cyclobenzaprine 10 mg
Date: September 2, 2025
Attention: All Providers
Effective date: August 27, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like inform providers that effective August 27, 2025, Unichem Pharmaceuticals (USA), Inc. voluntarily recalled one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg to the consumer level. The Cyclobenzaprine 10 mg (90-count) label was inadvertently placed on bottles containing Meloxicam 7.5 mg tablets.
Product affected:
Impacted Medication
NDC No.
Lot No.
Expiration Date
CYCLOBENZAPRINE HYDROCHLORIDE TABELTS USP 10 MG
29300-415-19
GMML24026A
Sept 2027
How this impacts providers: This recall may affect providers whose patients were dispensed the impacted lot, as members may unknowingly be taking Meloxicam instead of Cyclobenzaprine. This could result in ineffective therapy for muscle spasms as well as the potential for adverse effects associated with unintended NSAID use. Providers should be aware that affected patients may contact their offices with questions or concerns and may need counseling regarding discontinuation of the recalled product and appropriate replacement therapy.
Next step for providers: Providers should inform their impacted patients and arrange for the return and replacement of the drug.
